专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004004750A3 USE OF ALANYL-AMINOPEPTIDASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS 审中-公开
标题翻译：抑制剂丙氨酰氨工具和这一综合药物制剂
公开(公告)号：WO2004004750A3
公开(公告)日：2004-05-06
申请号：PCT/EP0307199
申请日：2003-07-04
申请人： INST MEDIZINTECHNOLOGIE MAGDEB , ANSORGE SIEGFRIED , TADJE JANINE , LENDECKEL UWE
发明人： ANSORGE SIEGFRIED , TADJE JANINE , LENDECKEL UWE
IPC分类号： A61K45/00 , A61K31/131 , A61K31/16 , A61K31/165 , A61K31/192 , A61K31/198 , A61K31/401 , A61K31/4035 , A61K31/4164 , A61K31/454 , A61K31/66 , A61K31/661 , A61K31/662 , A61K31/69 , A61K38/00 , A61K38/17 , A61K39/00 , A61P1/04 , A61P5/16 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/06 , A61P37/08 , A61P43/00
CPC分类号： A61K31/66 , A61K38/1709 , A61K2300/00
摘要： The invention relates to the use of one or several alanyl-aminopeptidase inhibitors and/or enzyme inhibitors which exhibit the same substrate specificity in order to stimulate the production of TFG-beta 1 and the expression of TFG-beta 1 in and/or on lymphocyte T regulators. The invention also relates to the use of said inhibitors for preventing and/or curing autoimmune, allergic and cardiovascular diseases and to preclude the rejection of transplants. In addition, said invention relates to applications in which peptidic fragments of pathogenic autoantigens or synthetic analogues and/or specific antigenic components of pathogenic microorganisms are used.
摘要翻译：本发明涉及使用抑制剂或丙氨酰基氨肽酶和/或用于诱导产生TGF-β1和TGF-β1的表达的中和/或上TregZellen相同的酶的底物特异性和防止使用几种抑制剂和/或治疗自身免疫性疾病，过敏症，动脉粥样硬化的，和用于移植排斥的抑制。本发明还涉及到在另外用途中致病自身抗原或合成的类似物，和/或致病性微生物的特异性抗原组分的肽片段一起使用。

2. 发明申请

WO02053170A3 COMBINED USE OF ENZYME INHIBITORS AND PHARMACEUTICAL PREPARATIONS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF ARTERIOSCLEROSIS, FOR THE TREATMENT AND PREVENTION OF ALLERGIC REACTIONS OF TYPE I ACCORDING TO THE GELL AND COOMBS CLASSIFICATION, AND FOR THE TREATMENT AND PREVENTION OF DERMATOLOGICAL DISEASES ASSOCIATED WITH FO 审中-公开
标题翻译：酶抑制剂和药物制剂及其用于治疗和动脉粥样硬化的预防结合使用，用于治疗和预防过敏性反应来I型和盖尔和库姆斯治疗和预防皮肤病滤泡及表皮HYPERKERATOS
公开(公告)号：WO02053170A3
公开(公告)日：2003-02-20
申请号：PCT/EP0115199
申请日：2001-12-21
申请人： INST MEDIZINTECHNOLOGIE MAGDEB , ANSORGE SIEGFRIED , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK , VETTER ROBERT , GOLLNICK HARALD
发明人： ANSORGE SIEGFRIED , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK , VETTER ROBERT , GOLLNICK HARALD
IPC分类号： C12N9/99 , A61K38/55 , A61K45/00 , A61P9/10 , A61P17/00 , A61P17/06 , A61P35/00 , A61P37/06 , A61P37/08 , A61K45/06
CPC分类号： A61K38/55 , A61K38/05 , A61K38/06 , A61K38/556 , A61K45/06 , A61K2300/00
摘要： The invention relates to the use of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same specific nature of substrate (DP IV enzyme activity), combined with inhibitors of alanyl aminopeptidase (aminopeptidase N, APN), or enzymes having the same specific nature of substrate (APN enzyme activity), for the additive to superadditive inhibition of the activation and proliferation (DNS synthesis) of human T lymphocytes or mononuclear cells and of the production of TH2 cytokines for the treatment and prevention of allergic reactions of type I according to the Gell and Coombs classification, for the additive to superadditive inhibition of the activation and proliferation (DNS synthesis) of human epidermal and follicular keratinocytes and those of the transitional region between the skin and the mucosa, and for the treatment and prevention of dermatological diseases associated with follicular and epidermal hyperkeratosis and reinforced keratinocyte proliferation. The invention also relates to the use of inhibitors of dipeptidyl peptidase IV (DP IV) and enzymes having the same specific nature of substrate (DP IV enzyme activity), combined with inhibitors of alanyl aminopeptidase (aminopeptidase N, APN), or enzymes having the same specific nature of substrate (APN enzyme activity), inhibitors of X-pro-aminopeptidase (aminopeptidase P, APP), inhibitors of the angiotensin-converting enzyme (ACE) and/or of prolyoligopeptidase (POP, prolylendopeptidase, PEP) for the additive to superadditive inhibition of the activation, DNS synthesis and proliferation of human T lymphocytes or mononuclear cells for the treatment and prophylaxis of arteriosclerosis. The invention further relates to pharmaceutical preparations comprising a plurality of inhibitors of enzymes of the above-mentioned groups.
摘要翻译：本发明涉及使用二肽基肽酶IV抑制剂（DP IV）以及具有组合相同的底物特异性（DP IV-类似酶活性）用具有相似的底物特异性丙氨酰基氨肽酶的抑制剂（氨肽酶N，APN）或酶的酶（APN-类似的根据盖尔和库姆斯和添加剂以超加和抑制的酶活性）的添加剂，以超加和抑制人T淋巴细胞或单核细胞和生产Th2细胞因子的活化和增殖（DNA合成）的，用于治疗和预防I型的过敏性反应的活化，增殖（DNA合成）的人表皮和毛囊角化细胞以及那些皮肤粘膜的过渡区以及用于治疗和预防皮肤疾病与表皮角化过度和滤泡和增加角化细胞增殖的。本发明还涉及使用二肽基肽酶IV（DP IV）的抑制剂，以及作为具有组合相同的底物特异性（DP IV-类似酶的活性）与丙氨酰基氨肽酶的抑制剂（氨肽酶N，APN）或酶（DP IV的底物特异性相同的酶为添加剂的超加和抑制活化的-Analogue酶活性），X-脯氨肽酶的（氨肽酶P，APP）中，“血管紧张素转化酶”的（ACE）和/或所述Prolyoligopeptidase（POP，脯氨酰内肽酶，PEP），DNA 合成和人T Lymphozaten或单核细胞用于治疗和预防动脉硬化的增殖。本发明还涉及一种包括多个上述基团的酶的抑制剂的药物制剂。

3. 发明申请

WO2005037779A3 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES 审中-公开
标题翻译：新的二肽基肽酶IV抑制剂对不同细胞分泌功能的影响和治疗免疫性炎症，神经和其他疾病
公开(公告)号：WO2005037779A3
公开(公告)日：2005-07-07
申请号：PCT/EP2004011645
申请日：2004-10-15
申请人： INST MEDIZINTECHNOLOGIE MAGDEB , KEYNEUROTEK AG , ANSORGE SIEGFRIED , BANK UTE , NORDHOFF KARSTEN , TAEGER MICHAEL , STRIGGOW FRANK
发明人： ANSORGE SIEGFRIED , BANK UTE , NORDHOFF KARSTEN , TAEGER MICHAEL , STRIGGOW FRANK
IPC分类号： A61K31/55 , C07C229/34 , C07C235/56 , C07C243/28 , C07C251/80 , C07C251/86 , C07C255/61 , C07C259/14 , C07C271/28 , C07C311/08 , C07C311/19 , C07C311/29 , C07C323/60 , C07C327/48 , C07D205/08 , C07D213/82 , C07D225/02 , C07D401/12 , C07D405/12 , C07D417/12 , C07F9/6506
CPC分类号： C07C235/56 , C04B35/632 , C07C229/34 , C07C243/28 , C07C251/80 , C07C251/86 , C07C255/61 , C07C259/14 , C07C271/28 , C07C311/08 , C07C311/19 , C07C311/29 , C07C323/60 , C07C327/48 , C07C2601/10 , C07C2603/74 , C07D205/08 , C07D213/82 , C07D225/02 , C07D401/12 , C07D405/12 , C07D417/12 , C07F9/65061
摘要： The invention relates to medicinally used substances which specifically inhibit peptidases splitting Gly-Pro-p-nitroanilide. The invention further relates to the use of at least one such substance or at least one pharmaceutical or cosmetic composition containing at least one such substance for preventing and treating diseases, particularly diseases with an overshooting immune response (autoimmune diseases, allergies, and transplant rejections), other chronic inflammatory diseases, neuronal diseases, brain damages, skin diseases (acne and psoriasis, among others), tumor diseases, and special viral infections (including SARS).
摘要翻译：本发明涉及特异性抑制甘氨酸 - 脯氨酸 - 对硝基苯胺裂解肽酶，用于药物中的物质。此外，本发明涉及使用在这样的物质或至少一个的至少至少一个这样的药物或化妆品组合物用于治疗疾病的预防和治疗，特别是用于治疗疾病与过冲从其他的免疫应答（自身免疫性疾病，变态反应和移植排斥），慢性预防和治疗物质容纳 -entzündlichen疾病，神经疾病和脑损伤，皮肤疾病（特别是痤疮和牛皮癣），肿瘤疾病和特定的病毒感染（包括SARS）。

4. 发明申请

WO2005004906A3 USE OF DP IV AND APN INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES INVOLVING THE HYPERPROLIFERATION AND MODIFIED DIFFERENTIATION CONDITIONS OF FIBROBLASTS 审中-公开
标题翻译：使用和DP IV抑制剂APN用于治疗与HYPER增殖和皮肤病成纤维细胞的改进差分状态
公开(公告)号：WO2005004906A3
公开(公告)日：2005-06-09
申请号：PCT/EP2004007377
申请日：2004-07-06
申请人： INST MEDIZINTECHNOLOGIE MAGDEB , ANSORGE SIEGFRIED , GOLLNICK HARALD , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK , VETTER ROBERT , SCHRAVEN BURKHART , THIELITZ ANJA , FAUST JUERGEN
发明人： ANSORGE SIEGFRIED , GOLLNICK HARALD , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK , VETTER ROBERT , SCHRAVEN BURKHART , THIELITZ ANJA , FAUST JUERGEN
IPC分类号： A61K45/06 , A61P17/00 , A61K38/55
CPC分类号： A61K45/06
摘要： The invention relates to a method for inhibiting the DNA synthesis of human fibroblasts that is necessary for proliferation, by the individual or combined action of inhibitors of alanyl-aminopeptidase (APN) and dipeptidylpeptidase IV (DP IV) that is expressed by said cells. The DNA synthesis (proliferation) of human fibroblasts is inhibited by a dosage-dependent administration of the APN and/or the DP IV. According to the invention, the application of inhibitors of the aforementioned enzyme or of preparations and administrable forms containing said inhibitors is eminently suitable for the treatment and prevention of dermatological diseases involving fibroblastic hyperproliferation and modified differentiation conditions of fibroblasts.
摘要翻译：本发明涉及一种通过由这些细胞丙氨酰氨肽（APN），和二肽基肽酶IV（DP IV）表示的蛋白的抑制剂的唯一或组合作用用于抑制人成纤维细胞的DNA合成所必需的增殖的方法。人成纤维细胞的DNA合成（增殖）是剂量依赖性通过APN和/或DP IV抑制剂给药抑制。我们的发明显示，上述酶的抑制剂或含有制剂和药物形式的这些抑制剂的施用它们适用于治疗和预防与过度增殖fibroblastar皮肤病学病症和分化成纤维细胞的修饰的状态。

5. 发明专利

CA2490714A1 USE OF ALANYL-AMINOPEPTIDASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS 未知
公开(公告)号：CA2490714A1
公开(公告)日：2004-01-15
申请号：CA2490714
申请日：2003-07-04
申请人： INST MEDIZINTECHNOLOGIE MAGDEB
发明人： ANSORGE SIEGFRIED , TADJE JANINE , LENDECKEL UWE
IPC分类号： A61K45/00 , A61K31/131 , A61K31/16 , A61K31/165 , A61K31/192 , A61K31/198 , A61K31/401 , A61K31/4035 , A61K31/4164 , A61K31/454 , A61K31/66 , A61K31/661 , A61K31/662 , A61K31/69 , A61K38/00 , A61K38/17 , A61K39/00 , A61P1/04 , A61P5/16 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要： The invention relates to the use of one or several alanyl-aminopeptidase inhibitors and/or enzyme inhibitors which exhibit the same substrate specificity in order to stimulate the production of TFG-.beta. 1 and the expression of TFG-.beta. 1 in and/or on lymphocyte T regulators. The inventi on also relates to the use of said inhibitors for preventing and/or curing autoimmune, allergic and cardiovascular diseases and to preclude the rejecti on of transplants. In addition, said invention relates to applications in which peptidic fragments of pathogenic autoantigens or synthetic analogues and/or specific antigenic components of pathogenic microorganisms are used.

6. 发明专利

CA2410305A1 COMBINATIONS OF ENZYME INHIBITOR-CONTAINING PREPARATIONS ANDTHE USE THEREOF 未知
公开(公告)号：CA2410305A1
公开(公告)日：2002-11-22
申请号：CA2410305
申请日：2001-05-22
申请人： INST MEDIZINTECHNOLOGIE MAGDEB
发明人： BROCKE STEFAN , ARNDT MARCO , LENDECKEL UWE , BUEHLING FRANK , NEUBERT KLAUS , ANSORGE SIEGFRIED , REINHOLD DIRK
IPC分类号： A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/4453 , A61K38/55 , A61K45/06 , A61P1/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/00 , A61P25/28 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要： The invention relates to a method which permits, owing to the simultaneous a nd joint inhibition of the enzyme activities of (I) alanyl-aminopeptidase and dipeptidyl-peptidase IV, (II) of the dipeptidyl-peptidase IV and the angiotensin-converting enzyme, (III) of the dipeptidyl-peptidase IV and prol yl- oligopeptidase, and of (IV) the dipeptidyl-peptidase IV and the X-Pro- aminopeptidase, to inhibit DNA synthesis and thus the proliferation of mononuclear cells as well as of T cells to an extent which cannot be obtaine d by the individual application of said enzyme inhibitors even when used in higher doses. Although the above-mentioned inhibitors influence the same process, namely DNA synthesis and thus the proliferation of immune cells, th is effect is not complete and not long-lasting when the inhibitors are used individually. The functional overlapping of the enzymatic activities results , as is supported by the experimental data, in an additive/super-additive inhibitory effect on DNA synthesis and the proliferation resulting from the simultaneous inhibition of a plurality of the above enzymes. The invention shows that the simultaneous application of inhibiting substances of the abov e- mentioned enzymes or of corresponding preparations and forms of administrati on is suitable for the therapy of autoimmune diseases and chronic diseases with an inflammatory genesis as well as for the treatment of post-transplant rejection episodes.

7. 发明专利

DE10102392A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors 未知
公开(公告)号：DE10102392A1
公开(公告)日：2002-08-14
申请号：DE10102392
申请日：2001-01-19
申请人： INST MEDIZINTECHNOLOGIE MAGDEB , ANSORGE SIEGFRIED
发明人： ANSORGE SIEGFRIED , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK
IPC分类号： A61K38/55 , A61K38/05
摘要： Inhibiting the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells and the production of TH2 cytokines comprises combined administration of dipeptidyl peptidase IV (DP IV) inhibitors and alanyl-aminopeptidase (aminopeptidase N, APN) inhibitors. The DP IV and APN inhibitors may be replaced by enzymes with the same substrate specificity. Independent claims are also included for the following: (1) the combined use of DP IV and APN inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human epidermal and follicular keratinocytes and those in the transition region between the skin and mucosa; (2) the combined use of DP IV and APN inhibitors, X-Pro-aminopeptidase (APP) inhibitors, ACE inhibitors and/or prolyloligopeptidase (POP) inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells; and (3) pharmaceutical preparations containing DP IV and APN inhibitors (or enzymes with the same substrate specificity) and optionally APP, ACE and/or POP inhibitors. ACTIVITY : Antiinflammatory; Immunosuppressive; Antiarteriosclerotic; Antipsoriatic; Dermatological; Virucide; Cytostatic. MECHANISM OF ACTION : Dipeptidyl peptidase inhibitor; Alanyl-aminopeptidase inhibitor; X-Pro-aminopeptidase inhibitor; Acetylcholine esterase inhibitor; Prolyloligopeptidase inhibitor. Human peripheral T-lymphocytes were incubated for 72 hours in the presence of Lys[Z(NO 2)]-thiazolidide (DP IV inhibitor) and actinoin (APN inhibitor), after which 3>[H]-thymidine incorporation was measured to determine the extent of DNA synthesis. Results showed a dosage-dependent (super-)additive inhibition of DNA synthesis.

8. 发明专利

DE10100052A1 Inhibiting DNA synthesis in T-lymphocytes, keratinocytes and TH2 cytokine production, comprises combined administration of dipeptidyl peptidase and alanyl-aminopeptidase inhibitors 未知
公开(公告)号：DE10100052A1
公开(公告)日：2002-07-11
申请号：DE10100052
申请日：2001-01-02
申请人： INST MEDIZINTECHNOLOGIE MAGDEB
发明人： ANSORGE SIEGFRIED , LENDECKEL UWE , NEUBERT KLAUS , REINHOLD DIRK
IPC分类号： A61K38/55 , A61K38/05 , A61K31/198
摘要： Inhibiting the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells and the production of TH2 cytokines comprises combined administration of dipeptidyl peptidase IV (DP IV) inhibitors and alanyl-aminopeptidase (aminopeptidase N, APN) inhibitors. The DP IV and APN inhibitors may be replaced by enzymes with the same substrate specificity. Independent claims are also included for the following: (1) the combined use of DP IV and APN inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human epidermal and follicular keratinocytes and those in the transition region between the skin and mucosa; (2) the combined use of DP IV and APN inhibitors, X-Pro-aminopeptidase (APP) inhibitors, ACE inhibitors and/or prolyloligopeptidase (POP) inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells; and (3) pharmaceutical preparations containing DP IV and APN inhibitors (or enzymes with the same substrate specificity) and optionally APP, ACE and/or POP inhibitors.

9. 发明专利

DE10025464A1 未知
公开(公告)号：DE10025464A1
公开(公告)日：2001-12-06
申请号：DE10025464
申请日：2000-05-23
申请人： INST MEDIZINTECHNOLOGIE MAGDEB
发明人： NEUBERT KLAUS , LENDECKEL UWE , ANSORGE SIEGFRIED , BUEHLING FRANK , REINHOLD DIRK , ARNDT MARCO
IPC分类号： A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/4453 , A61K38/55 , A61K45/06 , A61P1/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/00 , A61P25/28 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要： The invention relates to a method which permits, owing to the simultaneous and joint inhibition of the enzyme activities of (I) alanyl-aminopeptidase and dipeptidyl-peptidase IV, (II) of the dipeptidyl-peptidase IV and the angiotensin-converting enzyme, (III) of the dipeptidyl-peptidase IV and prolyl-oligopeptidase, and of (IV) the dipeptidyl-peptidase IV and the X-Pro-aminopeptidase, to inhibit DNA synthesis and thus the proliferation of mononuclear cells as well as of T cells to an extent which cannot be obtained by the individual application of said enzyme inhibitors even when used in higher doses. Although the above-mentioned inhibitors influence the same process, namely DNA synthesis and thus the proliferation of immune cells, this effect is not complete and not long-lasting when the inhibitors are used individually. The functional overlapping of the enzymatic activities results, as is supported by the experimental data, in an additive/super-additive inhibitory effect on DNA synthesis and the proliferation resulting from the simultaneous inhibition of a plurality of the above enzymes. The invention shows that the simultaneous application of inhibiting substances of the above-mentioned enzymes or of corresponding preparations and forms of administration is suitable for the therapy of autoimmune diseases and chronic diseases with an inflammatory genesis as well as for the treatment of post-transplant rejection episodes.

10. 发明专利

CA2410305C PREPARATIONS COMPRISING COMBINATIONS OF ENZYME INHIBITORS, AND THE USE THEREOF 未知
公开(公告)号：CA2410305C
公开(公告)日：2010-02-02
申请号：CA2410305
申请日：2001-05-22
申请人： INST MEDIZINTECHNOLOGIE MAGDEB
发明人： BROCKE STEFAN , REINHOLD DIRK , ARNDT MARCO , ANSORGE SIEGFRIED , NEUBERT KLAUS , LENDECKEL UWE , BUEHLING FRANK
IPC分类号： A61K45/06 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/4453 , A61K38/55 , A61P1/04 , A61P3/10 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/00 , A61P25/28 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00
摘要： The invention comprises a process wherein the DNA synthesis and, thus, the proliferation of mononuclear cells (MNZ) and of T cells as well is inhibited by the simultaneous and combined inhibition of the enzyme activity (I) of alanyl aminopeptidase and of dipeptidyl peptidase IV; (Ir) of dipeptidyl peptidase IV and of the angiotensin-converting enzyme; (III) of dipeptidyl peptidase IV and of prolyl oligopeptidase; and (IV) of di-peptidyl peptidase IV and of X-Pro-aminopeptidase to an extent which cann ot be achieved by an application of a single one of said enzyme inhibitors, even a t a higher dosage. Although the said inhibitors exercise an influence on the very same process finally, i.e. the DNA synthesis and, thus, the proliferation of immune cells , this effect is not complete and is not long lasting when a single inhibitor is applied. Fro m the functional overlap of enzymatic activities results an additive/superadditive inhibitory effect on the DNA synthesis and proliferation by the simultaneous inhibition of mor e than one of the above enzymes, as our data show. Our invention shows that the simultaneous application of substances inhibiti ng the above enzymes or of corresponding preparations and administration forms, respectively, is well suitable for a therapy of autoimmune diseases and chronic diseases with an inflammatory genesis as well as for a treatment of rejection episodes after a transplantation.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式